Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

130.59 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

50 51 Next >

Interview With David Rolfe of Wedgewood Partners ↗

February 17, 2023

Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe.

Via The Motley Fool

I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said. ↗

February 17, 2023

We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right?

Via InvestorPlace

How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula

February 17, 2023

New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.

Via MarketBeat

Why Cardiovascular Systems Stock Is Soaring Today ↗

February 09, 2023

The medtech company has agreed to a buyout offer from Abbott Laboratories.

Via The Motley Fool

Is This Dividend King a Buy for Income Investors? ↗

February 07, 2023

This healthcare company has one of the most established payouts in its sector.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Abbott Laboratories ↗

January 26, 2023

Via Benzinga

7 Hot Healthcare Stocks With the Potential to Outperform ↗

February 15, 2023

These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong.

Via InvestorPlace

Which Healthcare Stock Is a Better Pick in 2023? ↗

February 14, 2023

With a potential recession on the horizon, healthcare stocks could be good picks for investors. Which of these three is best?

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

February 14, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Better Buy: Johnson & Johnson or AbbVie? ↗

February 14, 2023

The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead.

Via The Motley Fool

Candy? Flowers? These Top Stocks Offer You Something Even Sweeter ↗

February 14, 2023

These stocks may reward you over time.

Via The Motley Fool

The 7 Most Undervalued Dividend Aristocrats to Buy ↗

February 13, 2023

With so many uncertainties ahead, investors may take comfort in the stability of the most undervalued dividend aristocrats to buy.

Via InvestorPlace

Abbott-Cardiovascular Systems Acquisition Could Further Add Uncertainty Over Surmodics' Product: Analyst Downgrades Stock ↗

February 13, 2023

Via Benzinga

Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million

February 09, 2023

Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and

Via Spotlight Growth

Why Is Cardiovascular Systems (CSII) Stock Up 48% Today? ↗

February 09, 2023

Cardiovascular Systems (CSII) stock is rising higher on Thursday following news that Abbott (ABT) intends to acquire the company.

Via InvestorPlace

Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M ↗

February 09, 2023

Via Benzinga

3 Dividend Stocks That Will Hold Up No Matter the Market Conditions ↗

February 08, 2023

These stocks could boost your portfolio in bear markets and bull markets.

Via The Motley Fool

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023? ↗

February 07, 2023

The healthcare stock fell 22% last year.

Via The Motley Fool

2 Beaten-Down Stocks With Stable Dividends to Buy In 2023 ↗

February 04, 2023

You can bet the farm on these companies' dividends.

Via The Motley Fool

3 Unstoppable Dividend Stocks to Buy in February ↗

February 04, 2023

All three belong to the elite group of stocks known as Dividend Kings.

Via The Motley Fool

2 Top Dividend Growth Stocks to Buy in February ↗

February 01, 2023

They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.

Via The Motley Fool

5 Top Stocks to Buy Now ↗

January 31, 2023

This eclectic mix of stocks will help diversify your portfolio.

Via The Motley Fool

Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January ↗

January 30, 2023

Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.

Via Talk Markets

GE Healthcare Technology: Speculating On Dividends

January 30, 2023

GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one.

Via MarketBeat

Is Abbott Laboratories a Good Dividend Stock to Buy Now? ↗

January 28, 2023

At least four Wall Street banks recently raised their price targets for the healthcare giant.

Via The Motley Fool

Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗

January 27, 2023

Stocks reacted well to uneven earnings and economic reports.

Via Investor's Business Daily

NIKE To Rally Over 23%? Here Are 10 Other Analyst Forecasts For Thursday ↗

January 26, 2023

Keybanc raised the price target for D.R. Horton, Inc. (NYSE: DHI) from $97 to $109. Keybanc analyst Kenneth Zener maintained an Overweight rating. D.R. Horton shares fell 1.6% to close at $95.48 on...

Via Benzinga

Abbott's Sales and Earnings Are Sinking: Should Investors Worry? ↗

January 26, 2023

There's more to the story than the negative trends for Abbott's top and bottom lines.

Via The Motley Fool

Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?

January 26, 2023

Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again.

Via MarketBeat

Topics Economy

Why Abbott Laboratories Stock Got Whacked on Wednesday ↗

January 25, 2023

Double beats for its latest quarter couldn't keep the bears away from the company's shares on Hump Day.

Via The Motley Fool

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Abbott Laboratories (NY:ABT)

All News about Abbott Laboratories

Starting at $3.75/week.

Subscribe Today